VERTEX PHARMACEUTICALS INC / MAVRTX
VERTEX PHARMACEUTICALS INC / MA Financial Overview 2021–2025
Vertex Pharmaceuticals returned to aggressive profitability in FY2025, generating $12.0 billion in revenue just one year after absorbing a massive $4.4 billion R&D charge for the Alpine Immune Sciences acquisition. This rapid financial turnaround validates the company’s strategy of leveraging its near-monopoly in cystic fibrosis (CF) to fund high-stakes expansion into pain management and gene editing without diluting shareholder equity. The top line demonstrates consistent momentum, with annual revenue climbing from $7.57 billion in FY2021 to the $12.0 billion record achieved in FY2025.
Beyond the headline numbers, the company is successfully executing its diversification pivot. The core CF franchise funded $3.9 billion in R&D expenses during FY2025, driving the commercial rollout of new therapies like JOURNAVX, which secured over 20,000 prescriptions within two months of its debut. Despite heavy capital deployment, the balance sheet remains fortress-like, ending the year with $12.3 billion in liquid assets to support further dealmaking and a new $4.0 billion share repurchase authorization. Investors rewarded this mix of stability and innovation, valuing the company at a $115.1 billion market cap and 29.6x earnings at the close of FY2025.
Recent Developments (Q3 and Q4 2025)
Momentum accelerated in Q3 2025, with quarterly product revenues rising 11% to $3.1 billion on the back of sustained cystic fibrosis demand. This growth underpinned a dramatic profitability turnaround, yielding $2.8 billion in net income for the first nine months of the year compared to a prior-year loss. Beyond the core franchise, the gene-editing therapy CASGEVY began contributing meaningful financial scale, generating $115.8 million in full-year revenue as reimbursement coverage expanded. Pipeline execution remains a key driver, highlighted by the rolling BLA submission for povetacicept in IgA nephropathy and advancements in the suzetrigine Phase 3 trials for neuropathic pain.
Bulls point to the successful commercialization of non-CF assets like CASGEVY as proof that the diversification strategy is taking hold. However, bears may argue the stock is priced for perfection, trading at 32.1x earnings with a $124.8 billion market capitalization as of the February 12, 2026 report date, leaving little room for clinical setbacks in the pain or kidney portfolios.
What to watch: Povetacicept BLA submission timeline; Suzetrigine Phase 3 data readouts.
Rev
$12.00B
FY2025
NI
$3.95B
FY2025
EPS
$15.46
FY2025
OCF
$3.63B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Feb 12, 2026)
Vertex Pharmaceuticals Incorporated (VRTX) has filed an 8-K report on February 12, 2026, announcing its consolidated financial results for the fourth quarter and full fiscal year ended December 31, 2025. While the specific financial figures are detailed in the press release (Exhibit 99.1), this filing serves as the official notification to the market of these results. Investors should refer to the press release for critical performance indicators, revenue streams, profitability, and any forward-looking statements or guidance provided by the company.
VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Nov 3, 2025)
Vertex Pharmaceuticals Incorporated (VRTX) filed an 8-K on November 3, 2025, to report its financial results for the three and nine months ended September 30, 2025. The primary purpose of this filing is to provide investors with timely information regarding the company's operational and financial performance. The press release detailing these results, attached as Exhibit 99.1, is the key document for investors seeking to understand the company's recent financial standing and progress. While this 8-K itself does not contain detailed financial figures, it serves as the official notification that the company has disseminated its quarterly earnings information. Investors are directed to the accompanying press release for specifics on revenue, earnings per share, pipeline updates, and any forward-looking statements. It's crucial for stakeholders to review Exhibit 99.1 to gain a comprehensive understanding of Vertex's financial condition and operational results for the period.
VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Aug 4, 2025)
Vertex Pharmaceuticals Incorporated (VRTX) has filed an 8-K report on August 3, 2025, announcing its financial results for the three and six months ended June 30, 2025. The detailed financial performance is available in the press release filed as Exhibit 99.1, which provides investors with key operational and financial data. In addition to financial reporting, the Company also disclosed the upcoming retirement of David Altshuler, Executive Vice President and Chief Scientific Officer, scheduled for August 1, 2026. This announcement signals a leadership transition within the scientific division, and investors will be keen to understand the succession plan and its potential impact on Vertex's research and development pipeline.
VERTEX PHARMACEUTICALS INC / MA 8-K Report, Corporate Update (May 19, 2025)
Vertex Pharmaceuticals Incorporated (VRTX) announced today a significant expansion of its capital return program with the authorization of a new $4.0 billion stock repurchase program, effective immediately. This new "2025 Repurchase Program" demonstrates management's confidence in the company's financial health and its commitment to enhancing shareholder value. The program has no expiration date and allows for flexibility in execution, including open market purchases and privately negotiated transactions, subject to market conditions and other strategic investment opportunities. This substantial new authorization complements the existing "2023 Repurchase Program," under which approximately $775 million remains available as of May 16, 2025. Combined, VRTX now has the authorization to repurchase up to $4.775 billion of its common stock. This aggressive buyback strategy signals a proactive approach to capital allocation, potentially reducing share count and increasing earnings per share over time, which should be viewed positively by investors.
VERTEX PHARMACEUTICALS INC / MA 8-K Report, Shareholder Vote Results (May 14, 2025)
Vertex Pharmaceuticals Incorporated (VRTX) held its annual shareholder meeting on May 14, 2025, with the results of key votes detailed in this 8-K filing. The company's Board of Directors saw all eleven nominated members overwhelmingly re-elected, indicating strong shareholder confidence in the current leadership and governance. Furthermore, the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified by a significant majority of shareholders. Investors will also note the advisory approval of the 2024 executive compensation program. However, a shareholder proposal concerning 'excessive golden parachutes' was not approved, suggesting that current executive compensation structures, despite the advisory vote on the 2024 program, remain a point of contention or scrutiny for a portion of the shareholder base. Overall, the meeting reflects broad support for the company's direction and governance framework, with a minor exception regarding executive compensation policies.
View all 8-K filings →